Health Care · In Vitro & In Vivo Diagnostic Substances

MYGN MYRIAD GENETICS INC SEC Filings & Insider Trading Activity 2026

company
CIK 899923141 filings
Russell 2000

MYGN at a glance

MYRIAD GENETICS INC (MYGN, SEC CIK 899923) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MYRIAD GENETICS INC (MYGN) reported revenue of $824.5 million (down 1.6% from FY2024) and a net loss of $365.9 million. Diluted EPS was -$3.95.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding MYRIAD GENETICS INC (MYGN) shares worth $234.5 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Davis Mark Steven on November 18, 2026 of 6,100 shares at $5.62 per share.
  • In the last 90 days, MYGN insiders reported 0 open-market purchases ($0) and 1 open-market sale ($34K) on Form 4, a net sale of $34K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$824.5M
−1.6% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$34K
13F holders
26 funds
$234.5M · −1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $202.7M, down $3.0M YoY from $205.7M
  • Cost-of-revenue margin 67.9% vs 69.9% YoY, with cost of revenue 32.1% vs 30.1%
  • Best segment Mental Health, revenue $39.5M vs $38.7M; worst Prenatal Health, $39.3M vs $44.5M
  • Cash $107.1M vs $149.6M at December 31, 2025, with operating cash use of $30.5M
  • Prenatal Health sale for $210M plus inventory, expected closing early 2027; reimbursement pressure and coverage limitations remain headwinds

Risk Factors

  • Newly added transaction risk: Prenatal Health sale to Laboratory Corporation of America for $210 million plus inventory remains subject to regulatory approvals
  • Regulatory risk: Hart-Scott-Rodino and state healthcare clearances could delay, condition, or block closing
  • Operational risk: Sale restrictions may limit Prenatal Business responses to market developments before closing
  • Financial risk: Lower post-sale revenue base increases risk of breaching the Credit Agreement revenue covenant
  • Liability risk: Myriad retains certain Prenatal billing, coding, reimbursement liabilities and indemnification obligations

AI summary of the MYGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • One-time retention options target executive continuity during operational-efficiency and financial-performance initiatives
  • CFO Benjamin Wheeler awarded options for 121,379 shares
Filed Nov 5, 2026Full analysis →

Item 8.01: Other Events

  • Unauthorized network access detected November 2, 2026, creating cybersecurity, privacy and operational risks
  • Testing operations and order management systems temporarily suspended during containment and investigation
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Myriad Genetics announced financial results for the three months ended September 30, 2026
  • Detailed results and management commentary appear in Exhibit 99.1, the attached earnings release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $202.7M, down 1% YoY, while average revenue per test rose 1% as payer and revenue-cycle initiatives gained traction
  • Core Cancer Care Continuum and Mental Health volume increased 3% YoY to 239,000 tests, offset by Prenatal volume declining 11%

AI summaries of MYGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MYGN

Don't miss the next MYGN filing

  • Alerts as it files. A push when MYGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MYGN, by share count.
  • Ask anything. An AI agent that reads every MYGN filing and answers with sources.

MYGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Davis Mark StevenSellNov 18, 2026$5.62
Muzzey DaleANov 6, 2026-
Sikri VishalANov 6, 2026-
Fox Jennifer LynneANov 6, 2026-
Jampa RajANov 6, 2026-
Wheeler Benjamin RichardANov 6, 2026-
Solaiman ShereenANov 6, 2026-
Verratti MarkANov 6, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$837.6M$824.5M
Gross Profit$517.0M$585.4M$576.6M
Operating Income--$123.5M-$387.2M
Net Income-$263.3M-$127.3M-$365.9M
Gross Margin-69.9%69.9%
Op. Margin--14.7%-47.0%
Net Margin--15.2%-44.4%
Balance Sheet
Total Assets$1.1B$1.0B$706.6M
Equity-$701.1M$368.0M
ROE--18.2%-99.4%
Per Share
EPS-$-1.41$-3.95
Cash Flow
Operating CF-$110.9M-$8.7M$1.8M

Source: XBRL data in MYRIAD GENETICS INC (MYGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MYGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MYGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$234.5M
Q2 202627$290.0M
Q1 202628$205.7M
Q4 202527$349.4M
Q3 202528$387.4M
Q2 202529$295.8M
Q1 202526$315.3M
Q4 202421$414.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MYGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
8-KNov 9, 2026Analysis-
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
8-KNov 4, 2026Analysis-
4Nov 2, 2026--
8-KOct 20, 2026Analysis-
8-KOct 9, 2026Analysis-
4Sep 22, 2026--
4Sep 17, 2026--
8-KSep 16, 2026Analysis-
4Sep 8, 2026--
SC 13GSep 4, 2026-
4Aug 17, 2026--
SC 13GAug 14, 2026-
SC 13GAug 7, 2026-
10-QJul 31, 2026Analysis
8-KJul 30, 2026Analysis-

Related Health Care companies

All Health Care →

MYGN SEC filings: frequently asked questions

Are MYGN insiders buying or selling?

In the last 90 days, MYRIAD GENETICS INC (MYGN) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $34,252 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MYGN stock?

As of September 30, 2026, the largest MYRIAD GENETICS INC (MYGN) holders among the 13F filers tracked by SignalX were BlackRock ($68.6 million), Millennium Management ($31.2 million), State Street Corp ($20.7 million), D.E. Shaw & Co ($20.2 million), Vanguard Capital Management LLC ($17.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MYGN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MYRIAD GENETICS INC (MYGN) reported revenue of $824.5 million (down 1.6% from FY2024) and a net loss of $365.9 million. Diluted EPS was -$3.95. The figures come from the XBRL data in the 10-K.

What did MYGN report in its latest 8-K?

MYRIAD GENETICS INC (MYGN) filed an 8-K on November 9, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). One-time retention options target executive continuity during operational-efficiency and financial-performance initiatives.

What are the latest MYGN SEC filings?

MYRIAD GENETICS INC (MYGN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 19, 2026.

What is MYGN's SEC CIK number?

MYRIAD GENETICS INC (MYGN)'s SEC Central Index Key (CIK) is 899923. EDGAR lists every MYGN filing under that number.

Ask anything about MYGN

The research agent reads MYGN's filings, financials, insider trades and 13F holders, then answers with sources.